Bio Break: Clinical Trials for Medical Devices vs. Pharmaceuticals

Resources

Bio Break: Clinical Trials for Medical Devices vs. Pharmaceuticals

Topic: Bio Break

In this episode of Bio Break, Joris van der Heijden and Nick Allan break down the key differences and similarities between clinical trials for medical devices and pharmaceutical products. As the conversation unfolds, they provide valuable insights into the distinct processes and challenges associated with these two types of trials, including the complexities of combination devices that bridge both worlds.

Nick begins by explaining the unique goals of clinical trials for medical devices. These trials focus on proving safety, efficacy, and the performance claims of the device in real-world settings. For example, diagnostic devices must demonstrate their ability to detect targets reliably and accurately, whether in a clinical laboratory or at the point of care.

In contrast, Nick outlines the four distinct phases of pharmaceutical clinical trials:

  • Phase 1: Conducted with healthy volunteers to evaluate safety and dosage, often involving a small group of participants (around 50 people).
  • Phase 2: Tests the drug’s efficacy in the target patient population, expanding the study to hundreds of participants.
  • Phase 3: Compares the drug against existing treatments or the standard of care in a much larger population, often with thousands of participants, to prove differentiation and effectiveness.
  • Phase 4: Post-market surveillance monitors long-term safety, side effects, and real-world performance after regulatory approval.

Nick highlights how medical device trials share parallels with pharmaceutical trials but often focus on different priorities, such as functional testing, usability, and regulatory claims. The discussion becomes especially intriguing when considering combination products, which integrate medical devices with pharmaceutical components, requiring alignment across both regulatory pathways and clinical trial objectives.

This episode is essential viewing for anyone working in medical device development, pharmaceuticals, or combination products. Gain a clear understanding of the clinical trial landscape and how these processes ensure safety, efficacy, and market readiness for innovative healthcare solutions.

Clinical Trials for Medical Devices vs. Pharmaceuticals

Brain-computer interface - A man wearing a brain-computer interface (BCI) headset sits in a clinical setting, concentrating as he appears to control a robotic arm with his mind. His head is overlaid with digital graphics representing brain activity. A doctor in a white lab coat stands nearby, monitoring the interaction. Onscreen data displays in the background suggest medical or neurological analysis. Bold text on the image reads "Brain-Controlled Tech?"

We explore the world of brain-computer interfaces (BCIs) and the challenges of capturing thought into action. Mark Drlik and Ariana Wilson walk through how these systems translate brain activity into control signals for devices—without needing surgical implants.

Person applying a white microneedle patch to their upper arm, with a red arrow pointing to the patch and a close-up of the microneedles on the right. Text reads “Painless!” to highlight the pain-free nature of the patch.

Nigel and Nick explore microneedle drug delivery—a growing field in medtech that aims to improve patient comfort and treatment compliance. While the term “microneedles” may sound futuristic, this technology has been around for years.

A 3D computational fluid dynamics (CFD) simulation result showing a scalar field contour in a branched tube system, with values ranging from 0.000 (blue) to 0.500 (red). The contour visualization highlights flow variation along the geometry, with red and orange indicating high scalar values in upper segments and blue-green regions representing lower values in the lower tube segments.

The impact of shear stress is critical to effectively design medical devices that handle biological fluids such as proteins or cell culture media. For example, non-physiological shear stress (NPSS) on blood is a key factor because hemolysis (cell rupture) could occur due to accumulated stress.